Q-omics provides the consensus-scored MIR409 profile across patient tissues and cancer cell-line models. MIR409 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MIR409 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, MIR409 RNA expression shows 11,608 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, BRCA, and TGCT as cancer lineages where MIR409 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR409 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR409 survival associations across molecular data types. MIR409 RNA expression shows survival associations in the most cancer types (11), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR409 RNA expression–survival associations across cancer types. High MIR409 expression shows unfavorable associations in BLCA, TGCT and LUAD, but favorable associations in LAML, ACC and STAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for MIR409 RNA expression.
This table summarizes MIR409 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR409. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR409 shows lower tumor expression in BRCA. The BRCA box plot shows higher MIR409 RNA expression in normal versus tumor tissue (log2 FC = −0.102, t-test p < 0.001).
This table shows molecular features associated with MIR409 in patient tissues and cancer cell lines. In patient samples, MIR409 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
